Page 53 - Demo

FOLFIRINOX reintroduction in pancreatic cancer513Table 1. Baseline patient characteristics in subsequent patient groups: all patients with palliative systemic treatment, first line FOLFIRINOX, FOLFIRINOX reintroduction after > 3 months therapy-free interval after first line FOLFIRINOX, second line nab-paclitaxel +gemcitabine after first line FOLFIRINOX and second line gemcitabine monotherapy after first line FOLFIRINOX. *Two patients treated with capecitabine-oxaliplatinirinotecan were also considered as FOLFIRINOX. Abbreviations: SRT, stereotactic radiotherapy; RFA, radiofrequent ablation; IRE, Irreversible electroporation.Baseline characteristics palliative systemic treatment(total)palliative FOLFIRINOXas firstsystemic treatment*FOLFIRINOX reintroductionSecond lineNab-paclitaxel +gemcitabineSecond line GemcitabineMonotherapyN 2092 1381 119 155 67Median age (y, range)65(25-87)63(25-83)64(39-79)61(25-80)63(43-82)Age > 70y (%) 563 (26,9) 229 (16,6) 25 (21) 22 (14,2) 12 (17,9)Male (%) 1138 (54,2) 760 (54,9) 58 (48,7) 88 (56,8) 34 (50,7)distant metastasis (%) 1563 (74,7) 1014 (73,2) 68 (57,1) 99 (63,9) 53 (79,1)WHO PS (%)0-123-4Missing1357 (64,9)210 (10,0)32 (1,5)493 (23,6)983 (71,2)90 (6,5)14 (10,1) 294 (21,3)96 (80,7)8 (6,7)-15 (12,6)118 (76,2)9 (5,8)2 (1,2)26 (16,8)51 (76,1)2 (3)1 (1,5)13 (19,4)No co-morbidity (%) 1057 (50,5) 778 (56,3) 66 (55,5) 85 (54,8) 37 (55,2)Local treatment (%)SRT RFA IRE125 (6,0)71 (3,4)26 (1,2)28 (1,3)112 (8,1)65 (4,7)22(1,6)25 (1,8)36 (30,3)14 (11,8)8 (6,7)14 (11,8)17 (11)9(5,8)6 (3,9)2 (1,3)2 (3)1 (1,5)1 1,5)needed a dose reduction after FOLFIRINOX reintroduction, compared to 73 of 119 patients (61.3%) during first line FOLFIRINOX. In this cohort 36 patients (30.3%) were treated with local therapy (majority LAPC; n=34, 94.4%).Table 2. FOLFIRINOX cycles during first line and reintroduction.FOLFIRINOX cyclesFirst line palliative FOLFIRINOX (all patients)First line palliative FOLFIRINOX(FOLFIRINOX reintroduction group)First line palliative FOLFIRINOX (Second lineNab-paclitaxel +gemcitabine group)First line palliative FOLFIRINOX (Second line gemcitabinemonotherapygroup)FOLFIRINOX reintroductionN 1381 119 155 67 119Median FOLFIRINOX cycles5 (range 1-32) 8 (range 2-19) 8 (range 1-31) 7 (range 1-20) 5 (range 1-28) patients with > 8 cycles363 (26,9%) 56 (48,3%) 66 (43,4%) 24 (35,8%) 23 (20%)patients with > 1 cycle1124 (83,3%) 116 (100%) 144 (94,7%) 61 (91%) 102 (88,7%)missing (n) 31 3 3 - 4